Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.
Earnings per share rose 46.81% year over year to ($0.25), which beat the estimate of ($0.39).
Revenue of $1,491,000 rose by 113.00% year over year, which beat the estimate of $220,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 11, 2020
Time: 07:05 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/r2c9xash
Company's 52-week high was at $3.66
Company's 52-week low was at $0.82
Price action over last quarter: down 53.20%
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.